CRBU - Caribou Biosciences: Under The Radar With Catalysts Approaching
2024-02-01 08:50:44 ET
Summary
- CRBU has provided regulatory and clinical updates in the past couple of months, but hasn't rallied quite like other biotech names.
- CRBU achieved alignment with the FDA on the comparator arm for its pivotal study of CB-010, and confirmed further data from the phase 1 ANTLER study in Q2'24.
- CRBU has progressed to the third dose level of CB-011 in the CaMMouflage study, and confirmed initial data are expected by year-end 2024.
In November 2023, I wrote about Caribou Biosciences ( CRBU ), rating it a buy based on the data with its off the shelf CAR-T therapeutic CB-010, from which I expected more positive data in 2024, its pipeline and plentiful cash. CRBU is up just 9% since then, despite positive updates and the larger rally in biotech. This article looks at those updates, and reconsiders the buy rating I originally gave CRBU....
Caribou Biosciences: Under The Radar With Catalysts Approaching